希罗达联合同步放化疗治疗晚期直肠癌疗效分析

目的：观察希罗达联合同步放化疗治疗晚期直肠癌的临床效果。方法选择2010年4月至2012年12月在我院肿瘤科接受治疗的晚期直肠癌患者116例，以随机数表法随机分为观察组和对照组各58例。对照组单用希罗达进行化疗，观察组采用希罗达联合放疗同步治疗。比较两组患者的治疗效果、治疗后不良反应、并发症，随访3年记录生存情况。结果观察组患者治疗后的CR比例及有效率分别为45.55%(27/58)、81.03%(47/58)，均明显高于对照组的27.59%(16/58)、56.09%(33/58)，差异均有统计学意义(P<0.05)；观察组患者出现血小板减少、血红蛋白降低以及淋巴细胞减少的比例分别为34.48%(20/58)、20.69%(12/58)、15.52%(9/58)，均明显低于对照组的53.45%(31/58)、39.66%(23/58)、31.03%(18/58)，但放射性直肠炎发生率为46.55%(27/58)，明显高于对照组的20.69%，差异均有统计学意义(P<0.05)；观察组患者3年总生存率为87.93%(51/58)，明显高于对照组的70.69%(41/58)，且观察组3年无转移生存率以及3年无复发生存率均明显高于对照组，差异均有统计学意义(P<0.05)。结论希罗达联合同步放化疗对晚期直肠癌患者具有很好的治疗效果，其不仅减少了治疗后血液学相关水平的波动频率，而且有效增加了治疗后生存率，在临床上具有较高的推广应用价值。

Clinical effect of xeloda combined with concurrent chemoradiotherapy in the treatment of advanced colorectal cancer

Objective To observe the clinical effect of xeloda combined with radiotherapy and chemotherapy in the treatment of patients with advanced rectal cancer. Methods A total of 116 patients with advanced rectal cancer, who admitted to the Department of Oncology of our hospital from April 2010 to December 2012, were randomly divided into observation group and control group by digital method, with 58 cases in each group. The control group was given chemotherapy with Xeloda alone, and the observation group received xeloda combined with radiotherapy treatment. The treatment effect, adverse reactions after treatment, complications, and survival record during 3-year follow-up of the two groups were compared. Results The complete responses (CR) and efficacy of the observation group 45.55% (27/58), 81.03% (47/58), respectively] were significantly higher than those of the control group 27.59% (16/58), 56.09%(33/58), respectively], P<0.05. The reduced proportion rate of platelet, hemoglobin and lymphocytes in the observation group 34.48% (20/58), 20.69% (21/58), 15.52% (9/58), respectively were significantly lower than those of the control group 53.45%(31/58), 39.66%(23/58), 31.03%(18/58) respectively, P<0.05. Appear radiation proctitis proportion rate of observation group 46.55% (27/58) was significantly higher than that of the control group 20.69% (12/58), P<0.05. The 3 years overall survival rate of observation group 87.93%(51/58)] was significantly higher than that of the control group 70.69%(41/58)], and the 3 years without metastasis survival rate and 3 years recurrence-free survival rate in the observation group were significantly higher than those in the control group (P<0.05). Conclusion Xeloda combined with synchronous radiotherapy and chemotherapy has a very good therapeutic effect in the treatment of advanced colorectal can-cer, which not only reduces the fluctuation frequency of hematological correlated level after treatment, but also effectively in-creases the survival rate for after operation. It has a high value in the clinical application and promotion.